Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine - AMLSG12-09

niversity Hospital Ulm0 个研究点目标入组 336 人开始时间: 2010年7月6日最近更新: 2016年10月24日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 336

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Both female and male patients meeting the mentioned inclusion and exclusion criteria will be included in this clinical trial, because the risk to get AML does not depend on a patient’s gender. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study
•Patients with suspected diagnosis of acute myeloid leukemia or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) classification)
•Patients considered eligible for intensive chemotherapy
•WHO performance status of = 2
•Age = 18 years. There is no upper age limit.
•No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis
•Non-pregnant and non-nursing. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration. Women of childbearing potential” is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months.
•Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for 3 month after the last dose of chemotherapy.
•Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner’s vasectomy). Hormonal contraception is an inadequate method of birth control.
•Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy. (while on therapy and for 3 month after the last dose of chemotherapy)
•Signed written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 269
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 67

排除标准

•The presence of any of the following will exclude a patient from study enrollment:
•AML with other recurrent genetic abnormalities (according to WHO 2008):
•AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
•AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
•AML with t(15;17)(q22;q12); PML-RARA (or variant translocations with other RARA gene fusions)
•AML with NPM1 mutation
•AML with FLT3 mutation
•Performance status WHO >2
•Patients with ejection fraction < 50% by MUGA or ECHO scan within 14 days of day 1
•Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or ALP >2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)
•Uncontrolled infection
•Severe neurological or psychiatric disorder interfering with ability of giving an informed consent
•Patients with a currently active” second malignancy other than non-melanoma skin cancers. Patients are not considered to have a currently active” malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.
•Known positive for HIV
•Bleeding disorder independent of leukemia
•No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation.
•No consent for biobanking.

研究者

发起方

niversity Hospital Ulm

相似试验

进行中（未招募）

1 期

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

EUCTR2009-016142-44-ATniversity Hospital Ulm336

进行中（未招募）

1 期

Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive breast cancer treated with neratinib plus loperamide versus neratinib dose escalation plus loperamide administered as needed versus neratinib plus loperamide plus colesevelamHER2+, HR+ Early stage Breast CancerMedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10083234Term: Hormone receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-001559-38-ESGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)315

招募中

1 期

EUCTR2019-001559-38-ITGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)315

已完成

2 期

Randomized phase II trial to evaluate the effectiveness of azacitidine for low risk MDS.lower risk myelodysplastic syndrome

JPRN-UMIN000010855ational Research Group on Idiopathic Bone Marrow Failure Syndromes100

已完成

2 期

A randomized phase II study for the evaluation of T cell depleted non-myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bortezomib and subsequent DLI for patients with multiple myeloma in progression or relapse following first line therapyKahlers disease10035227Multiple Myeloma

NL-OMON36688HOVO110